Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
View Patent ↗Pyrazole compounds substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl, are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases.
1. A compound which is selected from the group consisting of:
3-(4-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
2-[1-(3-fluorophenyl)-1H-pyrazol-4-yl]pyridine;
3-(1-pyridin-2-yl-1H-pyrazol-4-yl)benzonitrile;
2-[4-(3-methoxyphenyl)-1H-pyrazol-1-yl]pyridine;
3-(3-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
3-(1-pyridin-2-yl-1H-pyrazol-3-yl)benzonitrile;
2-[1-(3-bromophenyl)-1H-pyrazol-4-yl]pyridine;
3-fluoro-5-(3-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
3-fluoro-5-(5-methyl-3-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
2-[1-(2,5-difluorophenyl)-1H-pyrazol-3-yl]pyridine;
3-(3,5-dimethyl-4-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
2-[1-(2,3,5,6-tetrafluoro-phenyl)-1H-pyrazol-3-yl]pyridine;
2-[1-(3,5-difluoro-phenyl)-1H-pyrazol-3-yl]-pyridine;
2-(1-pentafluorophenyl-1H-pyrazol-3-yl)-pyridine;
2-[1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-pyridine;
2-[1-(2,3,5,6-tetrafluoro-4-methyl-phenyl)-1H-pyrazol-3-yl]-pyridine;
2-[1-(3-nitro-phenyl)-1H-pyrazol-3-yl]-pyridine;
3-fluoro-5-(4-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
2-{1-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-pyrazol-4-yl}pyridine;
4-(4-pyridin-2-yl-1H-pyrazol-1-yl)pyridine-2-carbonitrile;
2-[1-(4-nitro-phenyl)-1H-pyrazol-3-yl]-pyridine;
3-(1-pyridin-2-yl-1H-pyrazol-3-yl)benzonitrile;
2-[4-(3-methylphenyl)-1H-pyrazol-1-yl]pyridine;
2-[1-(3-fluoro-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(3,4-dimethyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(4-phenoxy-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(3-methoxy-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(2-benzyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(4-isopropoxy-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(3-ethyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(3-trifluoromethoxy-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(2-fluoro-5-trifluoromethyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(3-tert-butyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(2,3,5-trifluorophenyl)-1H-pyrazol-3-yl]pyridine;
3-(3-pyridin-2-yl-1H-pyrazol-1-yl)-5-(trifluoromethyl)benzonitrile;
3-[(5-chloropyridin-3-yl)oxy]-5-(3-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
2-(3-pyridin-2-yl-1H-pyrazol-1-yl)isonicotinonitrile;
2-[1-(3,5-dibromophenyl)-1H-pyrazol-3-yl]pyridine;
3-bromo-5-(3-pyridin-2-yl-1H-pyrazol-1-yl)benzonitrile;
2-{4-[3-fluoro-5-(pyridin-3-yloxy)phenyl]-1H-pyrazol-1-yl}pyridine;
2-[1-(3-bromo-5-fluorophenyl)-1H-pyrazol-3-yl]pyridine;
3-[(3-pyridin-2-yl-1H-pyrazol-1-yl)methyl]benzonitrile;
2-[1-(2,4-difluorophenyl)-1H-pyrazol-3-yl]pyridine;
4-[(4-pyridin-2-yl-1H-pyrazol-1-yl)methyl]benzonitrile;
3-[(4-pyridin-2-yl-1H-pyrazol-1-yl)methyl]benzonitrile;
6-(4-pyridin-2-yl-1H-pyrazol-1-yl)nicotinonitrile;
2-[(4-pyridin-2-yl-1H-pyrazol-1-yl)methyl]benzonitrile;
2-[1-(3,5-bis-trifluoromethyl-phenyl)-1H-pyrazol-3-yl]-pyridine;
2-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]pyridine;
4-(1-pyridin-2-yl-1H-pyrazol-4-yl)benzonitrile;
2-{4-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl}pyridine;
2-{4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl}pyridine;
2-[4-(3-fluorophenyl)-1H-pyrazol-1-yl]pyridine;
2-[1-(3-bromo-4-methylphenyl)-1H-pyrazol-4-yl]pyridine;
2-[1-(4-bromo-3-methyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(4-sec-butyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(4-propyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(4-cyclohexyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2,2-dimethyl-propionic acid 4-(4-pyridin-2-yl-pyrazol-1-yl)-phenyl ester;
2,2-dimethyl-propionic acid 4-(4-pyrimidin-4-yl-pyrazol-1-yl)-phenyl ester;
2-[1-(2-propyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
dimethyl-carbamic acid 4-(4-pyridin-2-yl-pyrazol-1-yl)-phenyl ester;
2-[1-(2,6-dimethyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(2-fluoro-4-methyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
2-[1-(3-bromo-2-methyl-phenyl)-1H-pyrazol-4-yl]-pyridine;
4-(3-pyridin-2-yl-1H-pyrazol-1-yl)benzoic acid;
2-{1-[3-(pyridin-4-yloxy)phenyl]-1H-pyrazol-3-yl}pyridine;
2-(3-pyridin-2-yl-1H-pyrazol-1-yl)-5-(trifluoromethyl)pyridine;
2-(1-phenyl-1H-pyrazol-3-yl)pyridine;
3-(3-pyridin-2-yl-1H-pyrazol-1-yl)benzoic acid;
2-{1-[3-fluoro-5-(pyridin-4-ylthio)phenyl]-1H-pyrazol-3-yl}pyridine; and
2-{1-[(4-methylphenyl)sulfonyl]-1H-pyrazol-3-yl}pyridine;
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition which comprises the compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.